# Safety, Tolerability and Efficacy of Single Dose Low Cost Minipool Intravenous Immunoglobulins in Moderately Severe Newly Diagnosed ITP

> **NCT02669277** · PHASE2 · UNKNOWN · sponsor: **Ain Shams University** · enrollment: 72 (estimated)

## Conditions studied

- Newly Diagnosed Pediatric ITP

## Interventions

- **DRUG:** IVIG prepared by minipool technology
- **DRUG:** standard IVIG product

## Key facts

- **NCT ID:** NCT02669277
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2016-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02669277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02669277, "Safety, Tolerability and Efficacy of Single Dose Low Cost Minipool Intravenous Immunoglobulins in Moderately Severe Newly Diagnosed ITP". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02669277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*